

6th Summer School on INtelligent signal processing for FrontIEr Research and Industry

28 August 2021



Margarita del Val

Viral Immunology

Centro de Biología Molecular Severo Ochoa (CSIC-UAM)











SALUD GLOBAL

6. MEDIOS, DIVULGACIÓN Y EDUCACIÓN

- Imagen de la ciencia
- Comunicación social: lucha 'fake news'
- Divulgación: ayudar a comprender la enfermedad
- Educación obligatoria en Salud global: protocolos de prevención, protocolos de contención; estilo de vida, alimentación

5. IMPACTO

- Social
- Político: instituciones, organizaciones internacionales
- Económico
- Impactos medioambientales
- Impacto en Dinámicas científicas y de innovación

I. PREVENCIÓN

- Origen: Historia; Cambio Global
- Diseminación del virus
- Protocolos de prevención: protección; vacunas; educación y estilo de vida
- Prevención económica

2. ENFERMEDAD

- Estructura del virus
- Genética de virus
- Infección y gravedad: factores agravantes y genéticos
- Respuesta inmune

3. CONTENCIÓN

- Propagación y epidemiología
- Diagnóstico y detección
- Protección: equipos, formación...
- Protocolos de contención: canales de comunicación y cooperación científico-institucionales

RESEARCH

Coordination
of over 330 research groups
from 91 CSIC Institutes
with over 110 funded grants
to confront the coronavirus pandemic
from all sides




Tratamiento y Análisis de Datos: Inteligencia Artificial



Transferencia de Tecnología

THANKS TO DONORS!




4.TRATAMIENTO

- Nuevos antivirales
- Reposición de fármacos
- Anticuerpos terapéuticos
- Vacunas
- Inflamación

SARS-CoV-2: he virus

The Microbe-scope PRIMARY TRANSMISSION METHOD airborne bites body fluids fecal-oral highly quite contagious not very very vaccinate now! 100% Rabies SARS-CoV-2 and other infectious agents: neither very 90% contagious, nor very lethal HIV no extremely deadly death likely 80% treatment Yet, it moves silently around ase fatality rate Maximal viral load: 1-3 days before symptoms (if any) Avian Flu (H5N1) From children to elderly: similar viral load, similar transmission T. C. Jones et al., Science 10.1126/science.abi5273 (2021). ethality We will all get infected MERS 40% deadly high chance 30% **Variants** C.Difficile 20% quite deadly 10% SARS Dengue Fever Diphtheria unlucky / unhealthy COVID-19/SARS-CoV-2 Whoot Measles Hepatitis B Measles not too deadly 0.1% Chickenpox high-risk groups (infants, the aged) Chicken Pox stomach bug' Transmissibility, basic reproduction number, R₀ likely to spread

Why this pandemic with SARS-CoV-2 Coronavirus? Nobody had any immunity




June 2020, ENE-COVID19 massive, representative, antibody detection in Spain:

Only 5% of the population had immunity


August 2021: estimated: 21% natural immunity + 68% fully vaccinated: <u>already / still only</u> ~75% immune population (2 doses, till 27/08/21, https://quemasqueremos.shinyapps.io/Shiny_pre/)

The immune system look at viruses

Infected cells




Our immune system eliminates foreign and harmful agents



the "city Police"


Our immune system is our best self-defense against the coronavirus




the "èlite units"

They eliminate virusinfected cells, where the virus multiplies rapidly

more "èlite units": antibodies





Antibodies neutralize circulating virus particles, so they cannot infect new cells

Naive unexperienced B lymphocytes

- Make IgM antibodies

Mature, experienced B lymphcoytes

- Make IgG antibodies

Intrinsic diversity of the primary antibody response: each single person has a personal repertoire of antibody sequences ready to go in her unexperienced B lymphocytes

Why do many infectious diseases never come back in a person?


Our lymphocytes learn and remember all pathogenic microbes they have ever encountered

B Lymphocyte

Some weeks...

Antibodybound virus

Why do many infectious diseases never come back in a person?




Immune MEMORY is the basis for vaccines

Immune MEMORY


B and T lymphocytes, the èlite cells that mediate long-lasting protection from re-infection

People who have never encountered the virus (all humankind)



Immunity after natural infection is solid, and confers ~97% protection from symptoms


People who already have encountered the virus (have suffered the infection and survived) (or have been vaccinated)




Common cold coronaviruses cause 10-15% of common colds: they also **contain virulence genes**As **everybody has certain immunity since childhood**:


- they seem benign
- they are seasonal

Immunity to common cold coronaviruses is also good but not optimal. **Antibodies also wane** with time, yet protection is good enough.





Interval duration between reinfections, 2-4 yrs




Most decrease, but some also present an **antibody boost after reinfection**

Seasonal coronavirus protective immunity is short-lasting


Edridge et al *Nat medicine* https://doi.org/10.1101/2020.05.11.20086439


Figure 1 Infection and reinfection characteristics, and waning immunity for seasonal coronaviruses.

SARS-CoV-2 coronavirus is not the worst infectious enemy ever ... had we got infected as children



The problem is we had / have no barriers: Complete lack of cellular and humoral immunity in humankind






Humoral immunity:


Neutralizing antibodies block infectious virus particles.

They recognize **variable** regions (epitopes) on **exposed** viral proteins





Cellular immunity:

Cytotoxic T lymphocytes destroy virus-infected cells, the viral factories. They recognize any region (epitope) of any viral protein




Immunity to viral infection is also long-lasting, and broader in specificity – but the risk is 100 to 100.000 times higher than any vaccine





The problem is we had /
have no defense: Complete
lack of cellular and humoral
immunity in humankind







- Primary infection entails no problem for those with a strong and balanced immune systems: Young people
- Primary infection of high risk and severity in those with a weak immune system that is skewed towards inflammation:

 Elderly Risk groups Immunodeficient
 - Elderly, Risk groups, Immunodeficient
 - → natural immunity is very protective to **97**% and long lasting


Humankind now has more defenses: VACCINES: 70-95 % protection





AN ARRAY OF VACCINES


All vaccines aim to expose the body to an antigen that won't cause disease, but will provoke an immune response that can block or kill the virus if a person becomes infected. There are at least eight types being tried against the coronavirus, and they rely on different viruses or viral parts.



Other efforts include testing whether existing vaccines against poliovirus or tuberculosis could help to fight SARS-CoV-2 by eliciting a general immune response (rather than specific adaptive immunity), or whether certain immune cells could be genetically modified to target the virus.

Genetic Vaccines

Vaccines that deliver one or more of the coronavirus's own genes into our cells to provoke an immune response.



95 % efficacy
Pfizer / BioNTech



BNT162b2 mRNA that encodes for SARS-CoV-2 spike protein.



Pre-S

Moderna



mRNA-1273

Synthetic messenger RNA that encodes for SARS-CoV-2 spike protein. Pre-S

95 % efficacy

62-90 % effective, Lancet

U. of Oxford AstraZeneca




AZD1222

Chimpanzee Adeno vector expressing SARS-CoV-2 spike protein.



Viral Vector Vaccines

Vaccines that contain viruses engineered to carry coronavirus genes. Some viral vector vaccines enter cells and cause them to make viral proteins. Other viral vectors slowly replicate, carrying coronavirus proteins on their surface.



CanSino Biologics



Ad5-nCoV

Ad5 vector expressing SARS-CoV-2 spike glycoprotein.





92 % effective, Lancet

VACCINE NAME: Sputnik 5 (formerly Gam-Covid-Vac)



JNJ-78436735

Ad26 vector expressing SARS-CoV-2 spike protein.


Pre-S



72 % effective

Protein-Based Vaccines

Vaccines that contain coronavirus proteins but no genetic material. Some vaccines contain whole proteins, and some contain fragments of them. Some pack many of these molecules on nanoparticles.






SARS-CoV-2 spike protein.

14/06/21: **90 % efficacy** (100 % death/hospital)



- •91% efficacy in high-risk populations
- •All COVID-19 hospitalizations/death occurred in the placebo group






16/06/21: **48 % efficacy**

(100 % death/hospital)

•Too low dose? 12 μg vs 30-100 μg



https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html



A vaccine

is a **medicine**

SAFE and **EFFICACIOUS**

that has **components of a microorganism**that estimulate the immune system to build **immune MEMORY**that is efficacious to **prevent infectious diseases**

Vaccines are safe

months



AstraZeneca (Vaxzevria) vaccine

Platelets decrease + unusual blood clots

~1 case in 100,000 vaccinees with one dose (316 in 36 millions in EU, 28/05) 8 times less after 2nd dose (10 million, in United Kingdom, 19/05) Severity has decreased because of awareness and early treatment Middle age adults


Comirnaty (Pfizer) and Spikevax (Moderna) vaccines

Severe anafilaxis

~1 case in 100,000 vaccinees Severity is controlled because of awareness and early treatment Pfizer, Moderna, AstraZeneca, Janssen vaccines are SAFE

after approval

Adverse effects: first 6 weeks after 2nd dose in each vaccinated person



years...



A vaccine

is a **medicine**

SAFE and **EFFICACIOUS**

that has **components of a microorganism**that estimulate the immune system to build **immune MEMORY**that is efficacious to **prevent infectious diseases**

That prevents

Pandemic-controlling vaccines: those that would also protect from transmission

- Asymptomatic infectior

There is NO protection from infection, only a 2-fold decrease (with Delta variant)


- Mild symptoms
- Severe symptoms
- death


anti covi<u>d</u>-19 vaccines: they protect from disease


 Virus transmission and spread (confer herd immunity)


¿NO? (viral load in vaccinees is almost the same)


Vaccination campaigns have to be very comprehensive in order to protect all at-risk













AS PART OF ITS MISSION TO SAVE LIVES, REDUCE POVERTY AND PROTECT THE WORLD AGAINST THE THREAT OF EPIDEMICS, GAVI HAS HELPED VACCINATE MORE THAN 822 MILLION CHILDREN IN THE WORLD'S POOREST COUNTRIES, PREVENTING MORE THAN 14 MILLION FUTURE DEATHS

Gavi, the Vaccine Alliance, helps vaccinate almost half the world's children against deadly and debilitating infectious diseases



GAVI, THE VACCINE ALLIANCE

PREMIO PRINCESA DE ASTURIAS DE COOPERACIÓN INTERNACIONAL 2020





When the pandemic strikes, no-one is safe until everyone is safe



Independent Panel for WHO Evaluation: 3 immediate actions:

Report of the Independent Panel for Pandemic Preparedness and Response: making COVID-19 the last pandemic. Ellen Johnson Sirleaf, Helen Clark. https://doi.org/10.1016/S0140-6736(21)01095-3

Minimal Goal in vaccination:

Health care professionals (3% population)

Goal: 20% population by the end of 2021

- 1. High income countries: supply **COVAX** with:
- 1,000 million **doses** by 1st September 2021 and 2,000 million doses by mid 2022.
- 2. High income countries and pharmaceutical companies producing vaccines: voluntary licensing of patents and technology transfer. If not in few months: compulsory.
- 3. Immediate commitment to supply in 2021 60% of promised **19,000 million** to the Accelerator **Access to COVID-19 Tools** (ACT).


India stopped supplying COVAX its vaccines during its severe wave: up to 190 million doses were held for Indians





6th Summer School on INtelligent signal processing for FrontIEr Research and Industry

28 August 2021



- We will all get infected, hopefully once we are safely vaccinated
- Variants evolve to be more transmisible, not to escape immunity
- With 15-20% of risk groups not vaccinated, new waves still as serious as before
- **Infection after vaccination is usually safer** (but for immunocompromised) and will each time **reinforce immune memory**
- Vaccines only protect the person who is vaccinated. Nonvaccinated people have the same risk of severity as always, and are now more exposed to silent transmissors.
- Vaccines are efficacious and safe
- Vaccines **MUST reach the whole planet**
- What is the risk of long-COVID among young low-risk gropus?













- Nos infectaremos todos, mejor que nos pille vacunados.
- Variantes mas transmisibles, no que se escapen
- Aprox la **mitad de la población todavía sin inmunidad**, aunque ya casi no son de grupos de alto riesgo
- La infección después de la vacunación no tiene casi riesgo, aunque reforzará y ampliará nuestra memoria inmunitaria
- La vacuna solo protege al vacunado; los no vacunados siguen teniendo el mismo riesgo que antes, pero con más contagiosos silenciosos.
- Vacunas eficaces y seguras
- Vacunar a todo el **planeta**
- ¿Qué riesgo y secuelas tienen qué jóvenes?



Mutaciones del coronavirus SARS-CoV-2

Los coronavirus mutan poco, 10 veces menos que la gripe, porque corrigen sus errores y no recombinan (la gripe sí)

pero en los grandes brotes se imponen rápidamente algunas nuevas mutaciones

Replicación masiva mundial, grandes brotes -

se imponen algunas variantes:

España, Julio-Agosto 2020

Reino Unido, B.1.1.7

Sudáfrica, B.1.351


Brasil, P.1

California, CAL.20C (B.1.427/B.1.429)

Los coronavirus de animales y humanos no tienen serotipos; nunca han logrado escapar de la respuesta de anticuerpos. La viruela, la polio, el sarampión tampoco – a pesar de replicación masiva mundial y vacunación masiva mundial.

Gripe A sí se escapa. Gripe B básicamente no.

neutralizing titers reduced 2-3.5 fold



McCallum et al. SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern

Science 01 Jul 2021 DOI: 10.1126/science.abi7994